Polivy Survival Improvement in Key Trials
Polivy (polatuzumab vedotin), combined with bendamustine and rituximab (BR), improved median overall survival (OS) by 7.8 months compared to BR alone in the Phase 3 POLARIX trial for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Patients on Polivy plus BR had a median OS of 19.4 months versus 12.4 months for BR alone (HR 0.77; 95% CI 0.62-0.96; p=0.02).[1][2]
In the Phase 2 ROMULUS trial for transplant-ineligible R/R DLBCL, Polivy plus BR/rituximab yielded a median OS of 12.4 months.[3]
How POLARIX OS Data Evolved
Initial 2021 data showed no OS benefit (HR 0.73; p=0.09), but longer follow-up in 2023 confirmed the gain after 720 events. Progression-free survival (PFS) improvement held steady at 39% risk reduction (median PFS 9.5 vs 5.6 months).[1][4]
Progression-Free vs Overall Survival
Polivy cut PFS risk by 39% in POLARIX (HR 0.61), but OS gains were smaller due to post-progression therapies like CAR-T. This gap reflects real-world second-line access challenges.[2][5]
Survival in Other Combinations
In frontline DLBCL (PCD13 trial), Polivy plus R-CHP improved 2-year OS to 88% vs 80% for R-CHOP (HR 0.51).[6] For R/R follicular lymphoma (Phase 2), Polivy plus BR/rituximab gave median OS not reached at 2.8 years.[7]
Patient Subgroups and Risks
OS benefit was consistent across IPI scores, but double-hit lymphoma patients saw less PFS gain. Common risks include neutropenia (42%), infections, and neuropathy; OS gains did not increase toxicity-driven deaths.[1][2]
[1]: NEJM: Polivy in R/R DLBCL (POLARIX)
[2]: Genentech Press: Updated POLARIX OS
[3]: Blood: ROMULUS Trial
[4]: ESMO 2023: POLARIX Update
[5]: FDA Label: Polivy
[6]: Lancet Oncology: PCD13
[7]: JCO: Follicular Lymphoma Data